Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
39
YCBD Quote, Financials, Valuation and Earnings
Last price:
$0.91
Seasonality move
:
-18.15%
Day range:
$0.87 - $0.96
52-week range:
$0.47 - $4.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.24x
P/B ratio:
1.14x
Volume:
673.9K
Avg. volume:
1.9M
1-year change:
-79.61%
Market cap:
$8.2M
Revenue:
$19.2M
EPS (TTM):
-$3.92
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
$4.8M | -- | -5% | -- | $2.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$298.6M | $0.20 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.4B | $2.63 | 110.49% | -58.59% | $479.79 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
SAVA
Cassava Sciences, Inc.
|
-- | -$0.68 | -- | -36% | $8.00 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
$0.92 | $2.00 | $8.2M | -- | $0.00 | 0% | 0.24x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$0.76 | $0.85 | $95.9M | 1.28x | $0.80 | 0% | 1.48x |
|
SAVA
Cassava Sciences, Inc.
|
$2.03 | $8.00 | $98.1M | -- | $0.00 | 0% | 2.69x |
|
SVRA
Savara, Inc.
|
$5.30 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
9.72% | 1.102 | 7.22% | 1.22x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -2.840 | 8.08% | 1.85x |
|
SAVA
Cassava Sciences, Inc.
|
-- | 4.633 | -- | 2.21x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
YCBD
cbdMD, Inc.
|
$2.5M | -$685.8K | -43.37% | -57.5% | -14.53% | -$243.5K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
SAVA
Cassava Sciences, Inc.
|
-$200K | -$11.9M | -86.98% | -86.98% | -- | -$6.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
cbdMD, Inc. vs. Competitors
-
Which has Higher Returns YCBD or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of 25.76%. cbdMD, Inc.'s return on equity of -57.5% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.53.28% -$0.08 $8M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About YCBD or ACAD?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.71%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that cbdMD, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe cbdMD, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is YCBD or ACAD More Risky?
cbdMD, Inc. has a beta of 2.140, which suggesting that the stock is 114.035% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock YCBD or ACAD?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or ACAD?
cbdMD, Inc. quarterly revenues are $4.7M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. cbdMD, Inc.'s net income of -$680K is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.24x -- $4.7M -$680K ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns YCBD or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of 20.1%. cbdMD, Inc.'s return on equity of -57.5% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.53.28% -$0.08 $8M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About YCBD or ALNY?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.71%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that cbdMD, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe cbdMD, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is YCBD or ALNY More Risky?
cbdMD, Inc. has a beta of 2.140, which suggesting that the stock is 114.035% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock YCBD or ALNY?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or ALNY?
cbdMD, Inc. quarterly revenues are $4.7M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. cbdMD, Inc.'s net income of -$680K is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.24x -- $4.7M -$680K ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns YCBD or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of -255.85%. cbdMD, Inc.'s return on equity of -57.5% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.53.28% -$0.08 $8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About YCBD or NBY?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.71%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could grow by 11.83%. Given that cbdMD, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe cbdMD, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is YCBD or NBY More Risky?
cbdMD, Inc. has a beta of 2.140, which suggesting that the stock is 114.035% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.135, suggesting its less volatile than the S&P 500 by 86.499%.
-
Which is a Better Dividend Stock YCBD or NBY?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. cbdMD, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or NBY?
cbdMD, Inc. quarterly revenues are $4.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. cbdMD, Inc.'s net income of -$680K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 1.48x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.24x -- $4.7M -$680K NBYNovaBay Pharmaceuticals, Inc.1.48x 1.28x $521K -$1.3M
-
Which has Higher Returns YCBD or SAVA?
Cassava Sciences, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -57.5% beat Cassava Sciences, Inc.'s return on equity of -86.98%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.53.28% -$0.08 $8M SAVACassava Sciences, Inc.-- -$0.22 $81.6M -
What do Analysts Say About YCBD or SAVA?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.71%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 294.09%. Given that Cassava Sciences, Inc. has higher upside potential than cbdMD, Inc., analysts believe Cassava Sciences, Inc. is more attractive than cbdMD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 SAVACassava Sciences, Inc.1 0 0 -
Is YCBD or SAVA More Risky?
cbdMD, Inc. has a beta of 2.140, which suggesting that the stock is 114.035% more volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -0.628, suggesting its less volatile than the S&P 500 by 162.76%.
-
Which is a Better Dividend Stock YCBD or SAVA?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or SAVA?
cbdMD, Inc. quarterly revenues are $4.7M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. cbdMD, Inc.'s net income of -$680K is higher than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.24x -- $4.7M -$680K SAVACassava Sciences, Inc.2.69x -- -- -$10.8M
-
Which has Higher Returns YCBD or SVRA?
Savara, Inc. has a net margin of -14.4% compared to cbdMD, Inc.'s net margin of --. cbdMD, Inc.'s return on equity of -57.5% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital YCBDcbdMD, Inc.53.28% -$0.08 $8M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About YCBD or SVRA?
cbdMD, Inc. has a consensus price target of $2.00, signalling upside risk potential of 116.71%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 104.01%. Given that cbdMD, Inc. has higher upside potential than Savara, Inc., analysts believe cbdMD, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings YCBDcbdMD, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is YCBD or SVRA More Risky?
cbdMD, Inc. has a beta of 2.140, which suggesting that the stock is 114.035% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock YCBD or SVRA?
cbdMD, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. cbdMD, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios YCBD or SVRA?
cbdMD, Inc. quarterly revenues are $4.7M, which are larger than Savara, Inc. quarterly revenues of --. cbdMD, Inc.'s net income of -$680K is higher than Savara, Inc.'s net income of -$29.6M. Notably, cbdMD, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for cbdMD, Inc. is 0.24x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income YCBDcbdMD, Inc.0.24x -- $4.7M -$680K SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
